论文部分内容阅读
目的探讨在本院由SARS(severeacuterespiratorysyndrome)冠状病毒引起的99例SARS患者合并肺炎支原体(Mycoplasmapneumoniae,MP)感染的临床情况变化。方法运用肺炎支原体抗体凝集实验,检测受SARS病毒感染的99例患者发病后的肺炎支原体抗体和滴度。结果99例SARS患者部分出现MP合并感染,阳性患者数为47例,总的阳性率为47.5%。在SARS发病前阶段,合并MP感染阳性率为69.3%(39/56),占整个阳性率的83.0%,并以高滴度分布较多;发病后阶段,合并MP感染阳性率为18.6%(8/43),占整个阳性率的17.0%,滴度较第一阶段偏低,两者有显著性差异(P<0.01)。结论SARS患者合并肺炎支原体感染,其感染率有阶段性差异,表明在前期感染SARS冠状病毒的患者毒性较强,对患者肌体影响较大,易出现肺炎支原体合并感染,而在后期的SARS冠状病毒感染者中,可能因毒性减弱,合并肺炎支原体感染率降低。
Objective To investigate the clinical changes of 99 SARS patients complicated with Mycoplasma pneumoniae (MP) infection caused by coronavirus (SARS) in our hospital. Methods Mycoplasma pneumoniae antibody agglutination test was used to detect mycoplasma pneumoniae antibody and titer in 99 patients infected with SARS virus. Results A total of 99 SARS patients were infected with MP. The number of positive patients was 47, with a total positive rate of 47.5%. In the pre-SARS stage, the positive rate of MP infection was 69.3% (39/56), accounting for 83.0% of the overall positive rate, with high titers; in the post-disease stage, the positive rate of MP infection was 18.6% 8/43), accounting for 17.0% of the total positive rate. The titers were lower than those in the first stage (P <0.01). Conclusion SARS patients with mycoplasma pneumoniae infection, the infection rate has a stage difference, indicating that in the early infection of SARS coronavirus patients with strong toxicity on the body of patients with a greater susceptibility to Mycoplasma pneumoniae infection, and in the late SARS coronavirus Infected, may be due to reduced toxicity, combined with reduced Mycoplasma pneumoniae infection.